# Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome

> **NCT00097370** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 78 (actual)

## Conditions studied

- Hypereosinophilic Syndrome

## Interventions

- **DRUG:** mepolizumab

## Key facts

- **NCT ID:** NCT00097370
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-09-30
- **Primary completion:** 2010-09-29
- **Final completion:** 2010-09-29
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** Study terminated by sponsor (29 Sep 2010). Subjects eligible to continue mepolizumab treatment were transferred into the compassionate use program (MHE104317)
- **Last updated:** 2017-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097370, "Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00097370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*